Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers

European Journal of Surgical Oncology

Volumn 34, Issue 7, 2008, Pages 734-738

  Arai, T ^a   Miyoshi, Y ^a   Kim, S J ^a   Akazawa, K ^b   Maruyama, N ^a   Taguchi, T ^a   Tamaki, Y ^a   Noguchi, S ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Breast cancer; Docetaxel; GSTP1; Paclitaxel; Primary systemic treatment

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; GLUTATHIONE TRANSFERASE P1; PACLITAXEL;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; GENE; GSTP1 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC MARKERS; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; PACLITAXEL; TAXOIDS;

EID: 45149087562     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.07.008     Document Type: Article

References (29)

1. Bonneterre J., Spielman M., Guastalla J.P., et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35 (1999) 1431-1439
2. Crown J., O'Leary M., and Ooi W.S. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9 Suppl 2 (2004) 24-32
3. Jones S.E., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 (2005) 5542-5551
4. Coles B.F., and Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. Biofactors 17 (2003) 115-130
5. Gilbert L., Elwood L.J., Merino M., et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 11 (1993) 49-58
6. Silvestrini R., Veneroni S., Benini E., et al. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89 (1997) 639-645
7. Huang J., Tan P.H., Thiyagarajan J., and Bay B.H. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 16 (2003) 558-565
8. Su F., Hu X., Jia W., Gong C., Song E., and Hamar P. Glutathion S transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 113 (2003) 102-108
9. Moureau-Zabotto L., Ricci S., Lefranc J.P., et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94 (2006) 473-480
10. Shen H., Kauvar L., and Tew K.D. Importance of glutathione and associated enzymes in drug response. Oncol Res 9 (1997) 295-302
11. Iwao-Koizumi K., Matoba R., Ueno N., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23 (2005) 422-431
12. Mathieu A., Remmelink M., D'Haene N., et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer 101 (2004) 1908-1918
13. Akazawa K., Tamaki Y., Taguchi T., et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12 (2006) 130-137
14. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
15. Jeronimo C., Costa I., Martins M.C., et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 9 (2003) 3413-3417
16. Krassenstein R., Sauter E., Dulaimi E., et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10 (2004) 28-32
17. Park J.S., Yamamoto W., Sekikawa T., et al. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 20 (2002) 333-338
18. Yu D.S., Lin J.C., Hsieh D.S., Chang S.Y., and Lee C.F. Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer. Arch Androl 52 (2006) 283-291
19. Schmidt M., Bachhuber A., Victor A., et al. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 129 (2003) 295-302
20. Miyoshi Y., Taguchi T., Kim S.J., Tamaki Y., and Noguchi S. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer 12 (2005) 11-15
21. Adler V., Yin Z., Fuchs S.Y., et al. Regulation of JNK signaling by GSTp. EMBO J 18 (1999) 1321-1334
22. Bernardini S., Bernassola F., Cortese C., et al. Modulation of GST P1-1 activity by polymerization during apoptosis. J Cell Biochem 77 (2000) 645-653
23. Wang T.H., Wang H.S., Ichijo H., et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273 (1998) 4928-4936
24. Esteller M., Corn P.G., Urena J.M., et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58 (1998) 4515-4518
25. Parrella P., Poeta M.L., Gallo A.P., et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10 (2004) 5349-5354
26. Shinozaki M., Hoon D.S., Giuliano A.E., et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11 (2005) 2156-2162
27. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
28. Gogas H., and Fountzilas G. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann Oncol 14 (2003) 667-674
29. Tham Y.L., Gomez L.F., Mohsin S., et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94 (2005) 279-284